Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from May 20, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 18, 2026 — +3% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$42.41 – $44.12Entry zone — fair-value band

$44.36Published — price the day we called it

$46.87Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$45.71Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 36 days.

At window close

+3%

realized, from the publication price to the last close inside the window

Peak gain

+16%

peak, from the publication price — not a realized return

S&P 500, same window

+3.8%

SPY over the identical days, dividend-adjusted

Window close

$45.71

last close inside the window, ended August 18, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published May 20, 2026

Predicted growth

+7%

over the measurement window

Target price

$46.87

the price the thesis aimed for

Entry zone

$42.41 – $44.12

the fair-value band we waited for

Price at publication

$44.36

published May 20, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is a steady health-care company led by its diabetes and obesity medicines. New trial coverage for Wegovy and a share buyback have calmed investors, but rivals in the GLP-1 space and weak price momentum limit short-term gains. Near current support, expected upside in the next few months is cautious, not aggressive.

Primary drivers

GLP-1 drugs drive the company's future sales and growth
Share buybacks make the stock more attractive to investors
Stable health-care business helps in volatile markets
Rising competition keeps expectations for gains modest

How it played out

NVO: target reached in 36 days

Lyra published NVO at 44.36 with a cautious 7% short-term growth thesis. The thesis pointed to diabetes and obesity medicines, share buybacks, and a stable healthcare business, while competition and weak price momentum limited the expected gain.

The stock reached 46.87 in 36 days and later peaked at 51.46 on July 29, a 16% gain. It ended the window at 45.71, below the target but above the 44.36 publication price. The thesis played out, and the target was exceeded inside the window.

What happened during the window

On June 6, 2026, Novo Nordisk reported phase 2 zenagamtide data, including up to 14.6% weight loss at week 36. On August 4, 2026, it reported adjusted Q2 sales growth of 7% at constant exchange rates and raised its full-year outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals